Meeting Details - The shareholder meeting was held on May 22, 2025, with both on-site and online voting options available [1][2] - A total of 623,719,364 shares were represented, with 156 shareholders participating, representing 111,431,281 shares, which is 17.8656% of the total voting shares [1] Voting Results - Proposal 1: The 2024 Board of Directors Work Report was approved with 120,970,158 votes in favor, accounting for 97.2919% of the valid votes [2][3] - Proposal 2: The 2024 Supervisory Board Work Report was also approved with the same voting results as Proposal 1 [2][3] - Proposal 3: The 2024 Annual Report and its summary received 120,974,694 votes in favor, representing 97.2955% of the valid votes [3][4] - Proposal 4: The 2024 Financial Settlement Report was approved with 120,968,294 votes in favor, accounting for 97.2904% of the valid votes [4][5] - Proposal 5: The 2024 Profit Distribution Plan was approved with 121,092,433 votes in favor, representing 97.3902% of the valid votes [5][6] - Proposal 6: The reappointment of the accounting firm was approved with 120,929,447 votes in favor, accounting for 97.2591% of the valid votes [6] - Proposal 7: The proposal for the 2025 comprehensive credit and guarantee limit was approved with 121,073,933 votes in favor, representing 97.3754% of the valid votes [6] Legal Opinion - The meeting and voting procedures were confirmed to be legal and valid according to relevant regulations and the company's articles of association [6]

Group 1 - The legal opinion letter confirms the legality of the convening and holding procedures of the 2024 annual general meeting of Chengdu Huasheng Technology Group Co., Ltd. [1][2] - The meeting was convened by the company's 13th Board of Directors and publicly announced on April 29, 2025, detailing the time, location, and agenda [2][3] - The meeting was held on May 22, 2025, combining on-site and online voting methods, with the location being the company's research complex in Chengdu [3][4] Group 2 - A total of 156 shareholders participated in the meeting, representing 124,337,351 shares, which is 19.9348% of the total voting shares [4] - The meeting's attendees included company directors, supervisors, senior management, and the lawyers from the law firm [4] - The voting results for various resolutions were as follows: - The 2024 Board of Directors' work report was approved with 120,970,158 votes in favor, 3,342,377 against, and 24,816 abstentions [6] - The 2024 Supervisory Board's work report received the same voting results as the Board of Directors' report [6] - The 2024 annual report was approved with 120,974,694 votes in favor, 3,342,377 against, and 20,280 abstentions [6] - The 2024 financial settlement report was approved with 120,968,294 votes in favor, 3,342,377 against, and 26,680 abstentions [6] - The profit distribution plan for 2024 was approved with 121,092,433 votes in favor, 3,218,238 against, and 26,680 abstentions [6] - The proposal to reappoint the accounting firm was approved with 120,929,447 votes in favor, 3,342,688 against, and 65,216 abstentions [6] - The proposal for the 2025 comprehensive credit application and guarantee limit was approved with 121,073,933 votes in favor, 3,202,438 against, and 60,980 abstentions [5][6] Group 3 - The legal opinion concludes that the meeting's convening, participant qualifications, and voting procedures were all in compliance with relevant laws, regulations, and the company's articles of association [6]

成都市高新区交子大道 333 号中海国际中心 E 座 602 室 电话：028-65585333 传真：028-66266533 邮编：610041 北京国枫（成都）律师事务所 关于成都华神科技集团股份有限公司 2024 年年度股东大会的 法律意见书 国枫律股字[2025]D0015 号 致：成都华神科技集团股份有限公司（贵公司） 北京国枫（成都）律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出 席并见证贵公司 2024 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律业务 管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法律业 务执业规则》"）等相关法律、行政法规、规章、规范性文件及《成都华神科技集团股 份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程序、 召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜，出 ...

证券代码：000790 证券简称：华神科技 公告编号：2025-020 成都华神科技集团股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开和出席的情况 1、会议召开的时间： （1）现场会议时间 2025年5月22日（星期四）下午14:00。 （2）网络投票时间 2025年5月22日，其中，通过深圳证券交易所交易系统进行网络投票的时间 为：2025年5月22日9:15--9:25，9:30--11:30，13:00--15:00；通过深圳证券交易所 互联网投票系统投票的时间为：2025年5月22日9:15至15:00期间的任意时间。 2、现场会议地点：成都市高新西区蜀新大道 1168 号公司一楼多功能厅 3、会议召开方式：现场表决与网络投票相结合 4、会议召集人：董事会 5、会议主持人：董事长黄明良先生 6、本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和公 司章程的规定。 7、出席的总体情况： （1）出席现场会议及网络投票股东情况： 公司总股份 623,719,364 股，通过现场和网络投票的 ...

Core Viewpoint - Huasheng Technology (SZ000790) has received an administrative regulatory decision from the Sichuan Securities Regulatory Bureau due to various accounting and internal control issues, leading to a requirement for corrective measures and warnings issued to key executives [2][4][5]. Group 1: Accounting Issues - The company has been found to have irregular accounting practices, including misclassification of advertising expenses as intangible assets by its subsidiary Hainan Rongsheng Hong Technology Co., Ltd. in 2021 [2]. - In 2023, another subsidiary, Tibet Kangyu Pharmaceutical Co., Ltd., recognized revenue from medical device sales without actual transfer of control to customers, leading to subsequent returns [2]. - Additionally, sales expenses from Chengdu Yuanhong Mineral Water Co., Ltd. were incorrectly accounted for in other subsidiaries, affecting performance assessment accuracy [2]. Group 2: Non-operational Fund Occupation - In 2021, Hainan Huasheng Development Holding Co., Ltd., a subsidiary, prepaid non-main business contract funds, which were later returned after five months, during which some funds flowed into companies controlled by the actual controller, constituting non-operational fund occupation [3]. Group 3: Internal Control Deficiencies - The internal control systems of the subsidiaries are inadequate, with issues such as improper expense reimbursement documentation and non-compliance with procurement management protocols [3]. - The company lacks a robust internal control system for large non-main business expenditures, leading to non-operational fund occupation in 2021 [3]. Group 4: Executive Accountability - Key executives, including Huang Mingliang (Chairman and President), Li Jun (Vice President and CFO), and Song Gang (Vice President), have been held responsible for the identified accounting and internal control issues [4][5]. Group 5: Company Performance - In 2024, Huasheng Technology reported revenue of 864 million yuan, a year-on-year decrease of 13.89%, and a net profit attributable to shareholders of -6.69 million yuan, down 124.19% [8]. - In the first quarter of 2025, the company achieved revenue of 127 million yuan, a decline of 29.21%, with a net profit of -14.59 million yuan, a drop of 740.09% year-on-year [9].

Group 1 - Sanofi's innovative drug company, Sangfor, has granted Pfizer exclusive global rights (excluding mainland China) for the development, production, and commercialization of the PD-1/VEGF bispecific antibody SSGJ-707, marking a significant milestone for domestic pharmaceutical companies in entering the global market [1] - Pfizer will pay a non-refundable and non-offsettable upfront payment of $1.25 billion, with potential milestone payments reaching up to $4.8 billion based on development, regulatory approval, and sales, along with a double-digit percentage sales revenue share based on product sales in authorized regions [1] Group 2 - Yipinhong announced the acquisition of a 15.25% stake in its subsidiary Guangzhou Rui'an Bo from minority shareholder Arthrosi for $6.8 million (approximately 49 million RMB) to enhance its market rights for the innovative drug AR882 in China and to promote efficient research and rapid market entry [2] - The transaction's pricing and the ongoing technical support from Arthrosi will be closely monitored for future clinical progress and market access efficiency [2] Group 3 - Huasheng Technology received an administrative regulatory measure from the Sichuan Securities Regulatory Bureau, which ordered the company to rectify issues related to accounting irregularities, non-operating fund occupation, and inadequate internal controls [3] - The regulatory action highlights weaknesses in the company's governance structure and compliance awareness, potentially affecting the rights of minority investors [3] Group 4 - Fosun Pharma announced the resignation of Rong Yang, CEO of its U.S. subsidiary, due to personal reasons, raising concerns about the continuity of leadership and strategic direction in the critical U.S. market for innovative drug commercialization [4] - The company is currently expanding its capabilities in the U.S. for both generic and innovative drug registration and commercialization [4]

Core Viewpoint - Chengdu Huasheng Technology Group Co., Ltd. received an administrative supervision decision from the Sichuan Securities Regulatory Bureau due to various accounting and internal control issues, which require corrective actions and warnings for responsible individuals [1][2][3]. Group 1: Administrative Supervision Measures - The company was found to have incorrectly recorded intangible assets and recognized revenue from medical device sales without actual transfer of control to customers, leading to issues with revenue recognition [1][2]. - There were instances of non-operating fund occupation and failure to disclose related party transactions with the actual controller, which violated internal control regulations [2][3]. - The responsible individuals, including the chairman and other executives, received warning letters for their lack of diligence in addressing these issues [3]. Group 2: Required Actions and Compliance - The company is required to conduct a thorough review of its financial accounting, fund usage, and internal control weaknesses, and to implement effective measures for rectification [3][4]. - A written report detailing corrective measures must be submitted to the regulatory authority within 30 days of receiving the decision [3][4]. - The company emphasized its commitment to improving compliance with laws and regulations, enhancing operational standards, and maintaining the interests of shareholders [4][5].

1.会计核算不规范。一是2021年子公司海南融盛弘科技有限公司将部分广告费用支出 错误计入无形资产。二是2023年子公司西藏康域药业有限公司(以下简称西藏康域)部分医 疗器械销售，在未发生实物流转，控制权未转移给客户的情况下即确认收入，且发生期后 退货。三是2023年子公司成都远泓矿泉水有限公司(存在业绩承诺)少量销售费用核算至其 他子公司，影响业绩考核测算精准性。上述情形不符合《企业会计准则第6号——无形资产》 第十二条第二款、《企业会计准则第14号——收入》第十三条第一款第三项及第四项、《企 业会计准则——基本准则》第五条相关规定。 证券代码：000790 证券简称：华神科技 公告编号：2025-019 成都华神科技集团股份有限公司 关于收到中国证券监督管理委员会四川监管局 行政监管措施决定书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 成都华神科技集团股份有限公司（以下简称"公司"）及相关责任人于近日收到中国证 券监督管理委员会四川监管局（以下简称"四川证监局"）出具的《关于对成都华神科技集 团股份有限公司采取责令改正并对黄明良等相关责任人采取 ...

Core Viewpoint - The company is facing challenges in its financial performance for 2024, with a significant decline in revenue and net profit, primarily due to strategic business adjustments and ongoing project developments [2]. Group 1: Financial Performance - In 2024, the company's operating revenue decreased by 13.89% year-on-year, resulting in a net profit loss [2]. - The decline in revenue and profit is attributed to the active contraction of the construction steel structure business, the ongoing trial production of the Shandong Lingkai project, and increased financial costs due to higher bank financing [2]. Group 2: Market Position and Competitive Advantage - The company has a strong market competitiveness and brand recognition in the pharmaceutical and health beverage sectors, with several products included in the medical insurance catalog [3]. - The company's health business segment, Huashen Blue Light, possesses rare mineral water resources, with its Biri 59 product having a silicate content of 59.99 mg/L, significantly exceeding national standards [3]. Group 3: Research and Development Focus - The company plans to focus on the in-depth exploration and secondary development of major traditional Chinese medicine products, particularly the Sanqi Tongshu capsules and Biyuan Shu, to enhance product application range and efficacy [4]. Group 4: Response to Industry Policy Changes - The company is closely monitoring changes in medical insurance payment reforms and drug procurement policies, aiming to enhance its risk resistance through market expansion and product quality management [5]. Group 5: New Market Expansion - The company is considering international market expansion based on its core traditional Chinese medicine products, which are recognized in the German Pharmacopoeia, while also planning to develop related health products and services [6]. Group 6: Asset Restructuring and Strategic Investment - The company will prudently evaluate asset restructuring and strategic investment opportunities based on its development strategy and market conditions [7].

Group 1: Financial Performance - In 2024, the company's operating revenue decreased by 13.89%, resulting in a net loss due to intensified market competition and rising costs [3] - The decline in revenue and profit was primarily due to the contraction of the construction steel structure business and the ongoing trial production phase of the Shandong Lingkai project, which has not yet generated sales [3] Group 2: Market Position and Competitive Advantage - The company has a strong market presence in the pharmaceutical and health beverage sectors, with key products like Sanqi Tongshu Capsules and Biyuan Shu Oral Liquid included in the National Basic Medical Insurance Catalog [3] - The company ranks first in Chengdu's bottled drinking water market, leveraging unique mineral resources that enhance its product offerings [3] Group 3: Research and Development Focus - Future R&D efforts will concentrate on deepening the development of major traditional Chinese medicine products, particularly those with significant market influence [4] - The company aims to enhance product application range and efficacy stability through quality standard improvements [4] Group 4: Response to Industry Changes - The company is closely monitoring industry policy changes, such as medical insurance payment reforms, to ensure stable business development [4] - Strategies include expanding outpatient market channels and enhancing product quality management to mitigate policy risks [4] Group 5: Future Growth Strategies - The company is considering international market expansion based on strategic planning and market conditions, particularly for its core traditional Chinese medicine products [4] - Plans to extend the product line and develop related health products to meet diverse customer needs are in place [4]